Using Electronic Pharmacy Intervention to Optimize Adherence to Beta-blocker Therapy in Patients With Heart Failure

Cardiology research, including landmark trials, has demonstrated that 3 beta-blockers (BBs), bisoprolol, carvedilol, and metoprolol succinate, reduce mortality in heart failure (HF) patients.^1-6 As a result, National Clinical Practice Guidelines strongly recommend using 1 of 3 BBs proven to reduce mortality in all stable patients who have current or prior symptoms of HF and reduced left ventricular ejection fraction (EF), unless contraindicated (Class I, Level of evidence A).^7-8